Valuation: Xencor, Inc.

Market Cap 180.38Cr 161.08Cr 150.27Cr 136.5Cr 256.87Cr 17TCr 259.37Cr 1.8TCr 705.65Cr 8.88TCr 677.26Cr 662.56Cr 29TCr P/E 2026 *
-7.89x
P/E 2027 * -7.41x
Enterprise Value 137.08Cr 122.41Cr 114.2Cr 103.74Cr 195.21Cr 13TCr 197.11Cr 1.37TCr 536.26Cr 6.75TCr 514.69Cr 503.51Cr 22TCr EV / Sales 2026 *
9.57x
EV / Sales 2027 * 14.8x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day+0.99%
1 week-1.09%
Current month-1.80%
1 month-3.28%
3 months+48.85%
6 months+100.00%
Current year+60.03%
1 week 22.56
Extreme 22.56
26.03
1 month 22.56
Extreme 22.56
26.35
Current year 10.38
Extreme 10.375
30.61
1 year 10.38
Extreme 10.375
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/06/26 Free

Director

30,906 0.0417%
10/04/26 Sell

Chief Financial Officer

3,499 0.0048%
05/03/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%-1.09%+97.58%+25.71% 180.38Cr
-3.19%-3.19%+44.60%+87.98% 7.47TCr
-15.86%-16.67%+3.92%+50.90% 5.87TCr
-2.39%-2.05%+4.29%+31.33% 4.84TCr
-6.35%-8.63%+293.39%+638.59% 4.31TCr
+0.30%-0.71%+29.05%+29.74% 4.25TCr
-3.82%-2.41%-0.27%+102.63% 4.14TCr
-2.13%+1.07%+7.51%+50.31% 3.13TCr
-3.35%-4.95%-13.38%-15.78% 2.39TCr
-1.24%-7.47%-37.90%+309.96% 2.22TCr
Average -3.69%-2.64%+42.88%+131.14% 3.88TCr
Weighted average by Cap. -4.82%-1.88%+43.50%+134.59%

Financials

2026 *2027 *
Net sales 14Cr 13Cr 12Cr 11Cr 20Cr 1.39TCr 21Cr 143.24Cr 56Cr 704.84Cr 54Cr 53Cr 2.27TCr 12Cr 11Cr 10Cr 9.21Cr 17Cr 1.18TCr 17Cr 121.67Cr 48Cr 598.67Cr 46Cr 45Cr 1.93TCr
Net income -24Cr -21Cr -20Cr -18Cr -34Cr -2.32TCr -34Cr -239.8Cr -94Cr -1.18TCr -90Cr -88Cr -3.79TCr -28Cr -25Cr -24Cr -22Cr -41Cr -2.76TCr -41Cr -284.54Cr -111.29Cr -1.4TCr -106.81Cr -104.5Cr -4.5TCr
Net Debt -43Cr -39Cr -36Cr -33Cr -62Cr -4.19TCr -62Cr -433.08Cr -169.39Cr -2.13TCr -162.57Cr -159.05Cr -6.85TCr -
Projected Income Statement - Annual - Xencor, Inc.
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
09/26/09 $24.50 +0.99% 21,88,135
07/26/07 $24.26 -0.41% 16,96,619
06/26/06 $24.36 -4.96% 12,45,800
05/26/05 $25.63 +3.18% 12,76,618
02/26/02 $24.84 +0.28% 10,97,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Xencor, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
24.26USD
Average target price
31.42USD
Spread / Average Target
+29.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Xencor, Inc.
  1. Stock Market
  2. Stocks
  3. XNCR Stock